- Conditions
- Asthma
- Interventions
- Mepolizumab IV, Mepolizumab SC, IV Placebo, SC Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Newport Beach, California • Riverside, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
- Biological · Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
- Conditions
- Eosinophilic Granulomatous Vasculitis
- Interventions
- Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis
- Interventions
- Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Gainesville, Florida • Rochester, Minnesota + 3 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Mepolizumab, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 806 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Mepolizumab 100 mg, Placebo matching mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 11
- States / cities
- Fort Smith, Arkansas • Fremont, California • Santa Ana, California + 8 more